Immunocore Holdings Stock Current Valuation
| IMCR Stock | USD 32.28 0.16 0.50% |
Valuation analysis of Immunocore Holdings helps investors to measure Immunocore Holdings' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 11/25/2024, Enterprise Value is likely to grow to about 3.1 B, though Enterprise Value Over EBITDA is likely to grow to (47.48). Fundamental drivers impacting Immunocore Holdings' valuation include:
Price Book 4.2746 | Enterprise Value 1.2 B | Enterprise Value Ebitda (45.82) | Price Sales 5.4505 | Enterprise Value Revenue 4.0324 |
Undervalued
Today
Please note that Immunocore Holdings' price fluctuation is very steady at this time. Calculation of the real value of Immunocore Holdings is based on 3 months time horizon. Increasing Immunocore Holdings' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Immunocore stock is determined by what a typical buyer is willing to pay for full or partial control of Immunocore Holdings. Since Immunocore Holdings is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunocore Stock. However, Immunocore Holdings' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 32.28 | Real 44.76 | Target 81.67 | Hype 32.59 | Naive 32.08 |
The intrinsic value of Immunocore Holdings' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immunocore Holdings' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immunocore Holdings helps investors to forecast how Immunocore stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunocore Holdings more accurately as focusing exclusively on Immunocore Holdings' fundamentals will not take into account other important factors: Immunocore Holdings Company Current Valuation Analysis
Immunocore Holdings' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunocore Holdings Current Valuation | 1.19 B |
Most of Immunocore Holdings' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunocore Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immunocore Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunocore Holdings is extremely important. It helps to project a fair market value of Immunocore Stock properly, considering its historical fundamentals such as Current Valuation. Since Immunocore Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunocore Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunocore Holdings' interrelated accounts and indicators.
Click cells to compare fundamentals
Immunocore Current Valuation Historical Pattern
Today, most investors in Immunocore Holdings Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunocore Holdings' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunocore Holdings current valuation as a starting point in their analysis.
Immunocore Holdings Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunocore Holdings has a Current Valuation of 1.19 B. This is 91.68% lower than that of the Biotechnology sector and 74.28% lower than that of the Health Care industry. The current valuation for all United States stocks is 92.81% higher than that of the company.
Immunocore Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunocore Holdings' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunocore Holdings could also be used in its relative valuation, which is a method of valuing Immunocore Holdings by comparing valuation metrics of similar companies.Immunocore Holdings is currently under evaluation in current valuation category among its peers.
Immunocore Holdings Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunocore Holdings from analyzing Immunocore Holdings' financial statements. These drivers represent accounts that assess Immunocore Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunocore Holdings' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 889.5M | 1.0B | 1.1B | 2.2B | 3.3B | 3.5B | |
| Enterprise Value | 875.0M | 939.1M | 900.8M | 1.9B | 3.0B | 3.1B |
Immunocore Holdings ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunocore Holdings' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunocore Holdings' managers, analysts, and investors.Environmental | Governance | Social |
Immunocore Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0522 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 1.19 B | ||||
| Shares Outstanding | 50.03 M | ||||
| Shares Owned By Insiders | 5.23 % | ||||
| Shares Owned By Institutions | 94.54 % | ||||
| Number Of Shares Shorted | 7.97 M | ||||
| Price To Book | 4.27 X | ||||
| Price To Sales | 5.45 X | ||||
| Revenue | 249.43 M | ||||
| Gross Profit | 54.11 M | ||||
| EBITDA | (51.65 M) | ||||
| Net Income | (55.29 M) | ||||
| Cash And Equivalents | 208.06 M | ||||
| Cash Per Share | 4.74 X | ||||
| Total Debt | 84.03 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 3.98 X | ||||
| Book Value Per Share | 7.55 X | ||||
| Cash Flow From Operations | 2.94 M | ||||
| Short Ratio | 32.19 X | ||||
| Earnings Per Share | (0.95) X | ||||
| Target Price | 52.51 | ||||
| Number Of Employees | 497 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 1.62 B | ||||
| Total Asset | 597 M | ||||
| Retained Earnings | (744.67 M) | ||||
| Working Capital | 389.8 M | ||||
| Net Asset | 597 M |
About Immunocore Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunocore Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunocore Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunocore Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Immunocore Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against Immunocore Stock
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.